SRA737 monotherapy study enrolment by dose level.
oropharyngeal carcinoma, ATM, mesothelioma, tumour, pancreatic cancer, HGSOC, esophageal carcinoma, cholangiocarcinoma
FALLOPIAN TUBE CARCINOMA, DISEASE, DNA DAMAGE, MESOTHELIOMA, TUMOUR, PANCREATIC CANCER, ESOPHAGEAL CARCINOMA, CHOLANGIOCARCINOMA
Patient numbers and tumour types enrolled in different cohorts in dose escalation and expansion phases of the study.In the Dose Escalation phase the patients described as having other disease included pancreatic cancer (1), mesothelioma (2), esophageal carcinoma (1) and cholangiocarcinoma (1). In the Expansion Phase the patients described as having other disease included fallopian tube carcinoma (1) and oropharyngeal carcinoma (1).The median age of patients in this study was 64 years (range 38–86 years) and the most common tumour types were HGSOC (Patients enrolled in tumour-type expansion cohorts were required to have genetic alterations hypothesized to confer sensitivity to Chk1 inhibition. Of the pre-specified alterations required for eligibility, the most frequently detected were tumour suppressors TP53 (56% of patients), PTEN (15% of patients) and CDKN2A/B (8% of patients); DNA damage response genes BRCA2 (8% of patients) and ATM (7% of patients); and oncogenic drivers KRAS (23% of patients), FBXW7 (9% of patients), and MYC (8% of patients).